Therapeutic effect of mycophenolate mofetil or cyclophosphamide in children with Henoch-Schönlein purpura nephritis of different age groups

• Published in: Zhongguo dang dai er ke za zhi 2023-11, Vol.25 (11), p.1113-1117
• Main Authors: DU, Pei-Wei, Wen, Yu-Bing, Chen, Chao-Ying, Tu, Juan, Li, Hua-Rong
• Format: Article
• Language: Chinese
• ISSN: 1008-8830
• DOI: 10.7499/j.issn.1008-8830.2306085

OBJECTIVESTo investigate the difference in the therapeutic effect of mycophenolate mofetil (MMF) or cyclophosphamide (CTX) in children with Henoch-Schönlein purpura nephritis (HSPN) of different age groups.METHODSA retrospective analysis was conducted on the clinical data of 135 children with HSPN who were treated with MMF or CTX in the Department of Nephrology, Children's Hospital Affiliated to Capital Institute of Pediatrics, from October 2018 to October 2020. According to the immunosuppressant used, they were divided into two groups: MMF group and CTX group, and according to the age, each group was further divided into two subgroups: ≤12 years and >12 years, producing four groups, i.e, the ≤12 years MMF subgroup (n=30), the >12 years MMF subgroup (n=15), the ≤12 years CTX subgroup (n=71), and the >12 years CTX subgroup (n=19). All children were followed up for at least 12 months, and the above groups were compared in terms of clinical outcomes and the incidence rate of adverse reactions.RESULTSThere was no